Skip to main content
INFU
NASDAQ Industrial Applications And Services

InfuSystem Posts Delayed Q3 Results: Revenue $37.6M, Adjusted EBITDA $9.4M, Guidance Reaffirmed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Positive
Importance info
7
Price
$13.15
Mkt Cap
$261.911M
52W Low
$7.29
52W High
$14.64
52W Position info
80% above low
Off High info
10% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

INFU sits 80% above its 52-week low of $7.29.

Summary

InfuSystem reported the Q3 2026 results it delayed on November 3: revenue of $37.6 million (up 3.0%, 10.2% pro forma), net income of $3.2 million and Adjusted EBITDA of $9.4 million, with full-year guidance reaffirmed.


Key Events · Earnings and Guidance · INFU

  • Delayed Q3 Results Released

    Net revenue came in at $37.6 million, up 3.0% from $36.5 million, and net income was $3.2 million, or $0.15 per diluted share, versus $2.3 million, or $0.11 per diluted share a year earlier.

  • Pro-Forma Growth Accelerates

    Excluding the restructured GE Healthcare contract, pro-forma revenue grew 10.2%, up from 1.7% in Q1 and 7.5% in Q2; Wound Care revenue rose $2.0 million, or 112%.

  • Margins Expand on Cost Cuts

    Adjusted EBITDA rose 12.5% to $9.4 million and margin expanded to 24.9% from 22.8%, helped by lower costs from the GE Healthcare restructuring and tapering ERP project spend.

  • Guidance Reaffirmed

    Full-year 2026 pro-forma revenue growth is still expected at 6% to 8%, with Adjusted EBITDA margins in the low-to-mid 20% range.


Analysis · INFU · Industrial Applications And Services

The Q3 2026 numbers InfuSystem held back on November 3 to review $4.2 million of ERP-related billing issues are now out, and they show no revenue problem. Net revenue rose 3.0% to $37.6 million, or 10.2% pro forma once the deliberately shrunk GE Healthcare contract is excluded, while Adjusted EBITDA climbed 12.5% to $9.4 million and margin expanded to 24.9%. Management reaffirmed full-year guidance of 6% to 8% pro-forma revenue growth and low-to-mid 20% Adjusted EBITDA margins. One item remains open: the working capital hit, with about $5.0 million of receivables tied up by the ERP billing disruption, of which roughly $1.3 million had converted to cash by October. Fourth-quarter cash conversion is the number to check against the November 10 call.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INFU was trading at $13.15 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $261.9M. The 52-week trading range was $7.29 to $14.64. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INFU - Latest Insights

INFU
Nov 09, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.68
Real-time Price: $14.35 info
Change: -$0.330 (-2%) info
Market Cap: $287.481M info
INFU
Nov 03, 2026, 8:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.84
Real-time Price: $14.35 info
Change: +$0.510 (+4%) info
Market Cap: $287.481M info